Literature DB >> 17928867

Expression of a pathogen-response program in peripheral blood cells defines a subgroup of rheumatoid arthritis patients.

T C T M van der Pouw Kraan1, L G M van Baarsen, C A Wijbrandts, A E Voskuyl, F Rustenburg, J M Baggen, B A C Dijkmans, P P Tak, C L Verweij.   

Abstract

Rheumatoid arthritis (RA) is a heterogeneous disease with unknown etiology. Here we aimed to distinguish RA subtypes based on peripheral blood (PB) gene expression profiles in comparison with a pathogen-response transcriptional program. PB was obtained from 35 RA patients and 15 healthy individuals. For expression profiling we used DNA microarrays. A combined cluster analysis of RA and control samples together with samples from a viral infection model revealed that the gene expression profile of a subgroup of RA patients (RA(A)) was reminiscent to that of poxvirus-infected macaques. Statistical analysis, followed by Gene Ontology analysis of the RA(A) patients confirmed that these patients form a distinct group, with activation of several host defense mechanisms that resemble a common host-pathogen response. Analysis of the promoter region of genes that were overexpressed in the RA(A) patients, revealed an enrichment of transcription factor binding sites for NF kappaB and interferon-activated transcription factors. Moreover, this subgroup of RA patients expressed significantly increased titers of anti-cyclic citrullinated peptide antibodies. We conclude that activation of a host-pathogen response defines a subgroup of RA patients characterized by increased autoreactivity against citrullinated proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17928867     DOI: 10.1038/sj.gene.6364438

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  18 in total

Review 1.  Interferons in autoimmune and inflammatory diseases: regulation and roles.

Authors:  Divaker Choubey; Kamal D Moudgil
Journal:  J Interferon Cytokine Res       Date:  2011-12       Impact factor: 2.607

2.  Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort.

Authors:  Clio P Mavragani; Dan T La; William Stohl; Mary K Crow
Journal:  Arthritis Rheum       Date:  2010-02

3.  Functional genomics and rheumatoid arthritis: where have we been and where should we go?

Authors:  James N Jarvis; Mark Barton Frank
Journal:  Genome Med       Date:  2010-07-28       Impact factor: 11.117

4.  A towards-multidimensional screening approach to predict candidate genes of rheumatoid arthritis based on SNP, structural and functional annotations.

Authors:  Liangcai Zhang; Wan Li; Leilei Song; Lina Chen
Journal:  BMC Med Genomics       Date:  2010-08-20       Impact factor: 3.063

Review 5.  Type I interferon in organ-targeted autoimmune and inflammatory diseases.

Authors:  Mary K Crow
Journal:  Arthritis Res Ther       Date:  2010-08-25       Impact factor: 5.156

6.  Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases.

Authors:  Terrance P O'Hanlon; Lisa G Rider; Lu Gan; Rick Fannin; Richard S Paules; David M Umbach; Clarice R Weinberg; Ruchir R Shah; Deepak Mav; Mark F Gourley; Frederick W Miller
Journal:  Arthritis Res Ther       Date:  2011-04-26       Impact factor: 5.156

7.  A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm.

Authors:  Paul P Tak
Journal:  Rheumatology (Oxford)       Date:  2011-09-02       Impact factor: 7.580

8.  Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis.

Authors:  Erik J M Toonen; Christian Gilissen; Barbara Franke; Wietske Kievit; Agnes M Eijsbouts; Alfons A den Broeder; Simon V van Reijmersdal; Joris A Veltman; Hans Scheffer; Timothy R D J Radstake; Piet L C M van Riel; Pilar Barrera; Marieke J H Coenen
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

9.  Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab.

Authors:  Tamarah D de Jong; Saskia Vosslamber; Marjolein Blits; Gertjan Wolbink; Mike T Nurmohamed; Conny J van der Laken; Gerrit Jansen; Alexandre E Voskuyl; Cornelis L Verweij
Journal:  Arthritis Res Ther       Date:  2015-03-23       Impact factor: 5.156

Review 10.  Transcription profiling of rheumatic diseases.

Authors:  Lisa G M van Baarsen; Carina L Bos; Tineke C T M van der Pouw Kraan; Cornelis L Verweij
Journal:  Arthritis Res Ther       Date:  2009-01-30       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.